Cytokine Signalling Forum

Publications





April 19

Données relatives à l'efficacité et à l'innocuité fondées sur les conditions historiques ou préexistantes observées au départ chez les patients atteints de polyarthrite rhumatoïde active traités au baricitinib

Combe B, Balsa A, Sarzi-Puttini P, Tony HP, de la Torre I, Rogai V, Durand F, Witt S, Zhong J, Dougados M.
Ann Rheum Dis. 2019 Aug;78(8):1135-1138.

In a post-hoc analysis, BARI 4 mg showed similar efficacy and safety during placebo-controlled and LTE observation periods regardless of the presence or absence of select comorbidities in RA patients. Patients with RA have a high prevalence of comorbidities. This post-hoc analysis investigated the effect of select comorbidities (depression, osteoporosis, hepatic, cardiovascular or pulmonary disorders) on the efficacy and safety of BARI 4 mg QD in patients with moderate-to-severe active RA and i...

Mots clefs: JAK, Baricitinib, Clinical, Safety

Traduit par: Farese